Core Viewpoint - The company, Kewei Medical, has announced its plan to issue H-shares and list on the Hong Kong Stock Exchange to enhance its global strategy and brand recognition [1] Group 1: Company Actions - Kewei Medical held its 16th board meeting and 15th supervisory meeting on August 7, where it approved the proposal for issuing H-shares and listing on the Hong Kong Stock Exchange [1] - The company aims to accelerate its global strategy and improve its overseas business development capabilities through this listing [1] Group 2: Strategic Intent - The issuance of H-shares is intended to enhance the company's brand image and recognition in international markets [1] - The company will consider the interests of existing shareholders and the conditions of domestic and foreign capital markets when determining the timing and window for the issuance [1]

Meeting Overview - The second board meeting of Kefu Medical Technology Co., Ltd. was held on August 7, 2025, with all 7 directors present, including independent director Wen Zhihao attending via communication [1] - The meeting was chaired by Chairman Zhang Min and complied with relevant laws and regulations [1] Board Resolutions - The board approved a proposal to issue overseas listed foreign shares (H shares) and apply for listing on the Hong Kong Stock Exchange to enhance the company's global strategy and brand recognition [1][2] - The proposal received unanimous support with 7 votes in favor, 0 against, and 0 abstentions [2] Listing Details - The H shares will be ordinary shares with a nominal value of RMB 1.00, to be issued in foreign currency [2] - The issuance will occur within 24 months after the shareholders' meeting approval or within an extended period if agreed by shareholders [2] - The issuance method includes public offering in Hong Kong and international placement to qualified institutional investors [3] Issuance Scale and Pricing - The number of H shares issued will not exceed 15% of the total share capital before the issuance, with an option for an additional 15% through an over-allotment option [4] - The pricing will consider existing shareholder interests, investor acceptance, and market conditions, determined by the board and overall coordinators [4][5] Target Investors and Distribution - The issuance will target global investors, including those from Hong Kong, Macau, Taiwan, and other foreign investors [5] - The allocation of shares will depend on the number of valid applications received during the public offering in Hong Kong [6] Fund Utilization - The funds raised will be used for product R&D, global sales network expansion, business development, and working capital [10][11] - The board will have the authority to adjust the use of funds based on regulatory feedback and actual needs [11] Corporate Governance Adjustments - The company plans to amend its articles of association and governance structure to comply with the requirements for H share issuance [14][15] - The board will be authorized to make necessary adjustments to the governance documents post-issuance [15] Independent Director Appointment - The board approved the election of Shen Nan as an independent director, effective upon shareholder meeting approval [18] Committee Adjustments - The composition of various board committees has been adjusted to enhance governance following the appointment of the new independent director [19] Regulatory Compliance - The issuance and listing plan must be submitted for approval to the China Securities Regulatory Commission and the Hong Kong Stock Exchange [2][9]

Core Viewpoint - Kefu Medical plans to issue H-shares and list on the Hong Kong Stock Exchange to enhance its global strategy and brand recognition [1] Group 1: Company Strategy - The company aims to accelerate its global strategic layout and improve its overseas business development capabilities [1] - The funds raised from the H-share issuance will be used for product R&D innovation, global sales network expansion, business development, brand marketing, and supplementing working capital [1] Group 2: Issuance Details - The issuance will consist of a public offering in Hong Kong and an international placement for qualified institutional investors [1] - The number of H-shares to be issued will not exceed 15% of the company's total share capital prior to the issuance, with an option for an overallotment of up to 15% based on market conditions [1] - Specific details regarding the issuance and listing are yet to be finalized [1]

Group 1 - The China Securities Regulatory Commission (CSRC) has requested Estun (002747.SZ) to provide additional explanations regarding inconsistencies in the identification of its controlling shareholder and the criteria used for this identification [1] - CSRC also requires Estun to clarify the specific situation regarding the pledged shares held by its controlling shareholder and the impact on the company's control and normal business operations, assessing whether it constitutes a situation that prohibits overseas listing [1] - Estun's subsidiary, Nanjing Dingpai Electromechanical Technology Co., Ltd., has faced foreign exchange administrative penalties, and the company must clarify whether fines were paid timely and if corrective actions were completed, as well as the implications for the upcoming listing [1] Group 2 - Estun is recognized as a leading enterprise in the Chinese industrial robot sector, maintaining the highest shipment volume among domestic companies in the industrial robot solutions market for several consecutive years [1] - According to Frost & Sullivan, Estun achieved a historic milestone in Q1 2025 by surpassing foreign brands in domestic industrial robot shipments, becoming the first domestic robot enterprise to lead the Chinese industrial robot solutions market [1]

Group 1 - The company, Puyuan Precision Electric (688337.SH), announced plans to issue shares overseas (H-shares) and list on the main board of the Hong Kong Stock Exchange to enhance its overall competitiveness and international brand image [1] - The initiative aims to utilize diversified financing channels in the international capital market [1] - The proposal is subject to approval by the company's shareholders and requires necessary filings and approvals from relevant government and regulatory agencies [1] Group 2 - The company is currently in discussions with relevant intermediaries, and specific details of the plan have not yet been finalized [1]

Group 1 - The company, Ningbo Joyson Electronic Corp, is in the process of applying for the public issuance of H shares and listing on the Hong Kong Stock Exchange [1][2] - The application for the issuance and listing was submitted to the Hong Kong Stock Exchange on January 16, 2025, and relevant application materials have been published on the exchange's website [1] - The company has stated that the application materials are preliminary drafts and may be updated or revised, advising investors not to make investment decisions based solely on this information [1] Group 2 - The issuance and listing are subject to approvals from regulatory bodies including the China Securities Regulatory Commission, the Hong Kong Securities and Futures Commission, and the Hong Kong Stock Exchange, indicating potential uncertainties [2] - The company will fulfill its information disclosure obligations based on the progress of these approvals [2]

Group 1 - The company, Guangzhou Ruoyuchen Technology Co., Ltd., is planning to issue H-shares and apply for listing on the Hong Kong Stock Exchange to enhance its capital strength and international brand image [1][2] - The company is currently discussing the details of the H-share issuance and listing with relevant intermediaries, and no specific details have been finalized yet [1][2] - The issuance and listing of H-shares will not result in changes to the company's controlling shareholder or actual controller [1] Group 2 - The H-share issuance and listing are subject to approval from the company's board of directors, supervisory board, and shareholders' meeting, as well as regulatory approvals from relevant government and regulatory bodies [2] - There is significant uncertainty regarding whether the H-share issuance and listing will pass the necessary reviews and approvals [2]

2025年8月5日，若羽臣(003010.SZ)公告称，公司正在筹划发行境外上市外资股（H股）股票并申请在香 港联合交易所有限公司主板挂牌上市。 公告指出，公司正与相关中介机构就本次发行H股并上市的相关工作进行商讨，关于本次发行H股并上 市的细节尚未确定。待确定具体方案后，本次发行 H 股并上市尚需视情况提交公司董事会、监事会和 股东大会审议，并需取得中国证券监督管理委员会、香港联交所和香港证券及期货事务监察委员会等相 关政府机构、监管机构备案、批准或核准。 ...

若羽臣公告，公司正在筹划发行境外上市外资股（H股）股票并申请在香港联合交易所有限公司主板挂 牌上市。截至目前，公司正与相关中介机构就本次发行H股并上市的相关工作进行商讨，关于本次发行 H股并上市的细节尚未确定。本次发行H股并上市不会导致公司控股股东和实际控制人发生变化。 ...

Group 1 - The company is planning to issue H-shares and apply for listing on the Hong Kong Stock Exchange to enhance its international brand recognition and competitiveness [1][2] - Currently, the company is in discussions with relevant intermediaries regarding the issuance and listing of H-shares, with specific details yet to be determined [1][2] - The issuance and listing of H-shares require approval from the company's board and shareholders, as well as regulatory bodies including the China Securities Regulatory Commission and the Hong Kong Stock Exchange [2]